Abstract
To obtain a license to be placed on the marketplace, a medicinal product must be accompanied by data on quality and data from preclinical studies and studies of clinical safety and efficacy. At the time of first production, a custom-made medicinal product will have data on quality but will not be accompanied by data from preclinical studies or from studies of clinical safety and efficacy. To span the gap in data, an “imperfect intellectual bridge” between data for a custom-made medicinal product and data for its master medicinal product is described. The imperfect intellectual bridge will allow the custom-made medicinal product to draw on data associated with its master medicinal product. In time, it may be possible for a custom-made medicinal product to transfer to an independent license after collection of data on clinical safety and efficacy by means of a pharmacovigilance exercise.
Similar content being viewed by others
References
Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf. Published 2012. Accessed September 2013.
Johnston JD, Feldschreiber P. Challenges posed to the European pharmaceutical regulatory system by highly-personalised medicines [published online June 6, 2013]. Br J Clin Pharmacol.
European Commission. Omics in personalised medicine. http://ec.europa.eu/research/health/pdf/summary-report-omics-for-personalised-medicine-workshop_en.pdf. Published 2010. Accessed September 2013.
Johns Hopkins University. *610142: centrosomal protein, 290-KD; CEP290. http://omim.org/entry/610142. Published 2013. Accessed October 2013.
Johnston JD, Feldschreiber P. Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligo-nucleotide medicinal products [published online October 8, 2013]. Br J Clin Pharmacol.
Council directive 93/42/EEC of 14 June 1993 concerning medical devices. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1993L0042:20071011:en:PDF. Published 1993. Accessed September 2013.
European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf. Published 2007. Accessed October 2013.
Coulter A, Parsons S, Askham J. Where are the patients in decision-making about their own care? http://www.who.int/management/general/decisionmaking/WhereArePatientsinDecisionMaking.pdf. Published 2008. Accessed October 2013.
Choi HW, Lee JH. Pharmaceutical product liability. In: Edwards LD, Fox AW, Stonier PD, eds. Principles and Practice of Pharmaceutical Medicine. 3rd ed. London, England: Blackwell Publishing Ltd; 2011:688–702.
Institute of Medicine of the National Academies. Building a national framework for the establishment of regulatory science for drug development. http://www.ncbi.nlm.nih.gov/books/n/nap12968/pdf/. Accessed November 2013.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johnston, J.D., Feldschreiber, P. The Imperfect Intellectual Bridge Between a Master Medicinal Product and Its Associated Custom-Made Medicinal Products. Ther Innov Regul Sci 48, 623–627 (2014). https://doi.org/10.1177/2168479013518933
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479013518933